Clinical study of Nd: YAG laser combined with triamcinolone acetonide in the treatment of oral submucosal fibrosis
-
摘要:
目的 采用Nd:YAG激光联合曲安奈德治疗口腔黏膜下纤维化患者,观察治疗后纤维化组织的修复、愈合及病情进展情况。 方法 选取2018年6月—2019年10月于杭州师范大学附属医院口腔科就诊的80例口腔黏膜下纤维化患者,采用随机数字表法分为观察组与对照组,每组40例。对照组患者使用曲安奈德注射液治疗,观察组在此基础上使用Nd:YAG激光治疗,2组均持续治疗9周。2组患者治疗前后采用视觉模拟评分法(VAS)评分进行评价,并测量张口程度和口腔黏膜病损面积;采用酶联免疫吸附法(ELISA)测定血清血管内皮生长因子(VEGF)、血小板反应蛋白(TSP)、基质金属蛋白酶-2(MMP-2)水平及血清IL-6、TNF-α水平。 结果 治疗后,对照组口腔黏膜病损面积为(1.47±0.62)cm2,观察组为(0.86±0.23)cm2,观察组口腔黏膜病损面积小于对照组(P < 0.05);2组患者血清VEGF均升高,观察组高于对照组[(0.75±0.19)pg/mL vs.(0.61±0.23)pg/mL, P < 0.05],而血清TSP、MMP-2、IL-6和TNF-α水平均降低,观察组低于对照组(均P < 0.05)。 结论 Nd: YAG激光联合曲安奈德可有效缓解口腔黏膜下纤维化患者口腔灼痛,抑制纤维化发展,并促进纤维化组织的修复与愈合,控制病情进一步发展。 Abstract:Objective To investigate the repair and healing of fibrotic tissue and the progress of the disease in patients with oral submucosal fibrosis after treatment with Nd: YAG laser combined with triamcinolone acetonide. Methods A total of 80 patients with submucosal oral fibrosis admitted to Affiliated Hospital of Hangzhou Normal University from June 2018 to October 2019 were selected, and random numbers were used. No significant difference was observed in VAS scores between the two groups after treatment (P>0.05). The area of oral mucosal lesions in the treatment group was smaller than that in the control group. According to table method, the patients were divided into treatment and control groups with 40 cases in each group. The control group was treated with triamcinolone acetonide injection, and the treatment group was treated with Nd: YAG laser on this basis. Both groups were treated continuously for 9 weeks. VAS score, mouth opening degree and oral mucosal lesion area, serum levels of VEGF, TSP, MMP-2, and serum levels of IL-6 and TNF-α were compared between the two groups before and after treatment. Results After treatment, the oral mucosal lesion area was (1.47±0.62) cm2 in the control group and (0.86±0.23) cm2 in the experimental group. The oral mucosal lesion area in the experimental group was lower than that in the control group (P < 0.05). Serum VEGF increased in both groups, and the treatment group was higher than the control group [(0.75±0.19) pg/mL vs. (0.61±0.23) pg/mL, P < 0.05], whereas serum TSP, MMP-2, IL-6, and TNF-α decreased, and the treatment group was lower than the control group (all P < 0.05). Conclusion Nd: YAG laser combined with triamcinolone acetonide can effectively relieve the burning pain in the mouth of patients with oral submucosal fibrosis, inhibit the development of fibrosis, promote the repair and healing of fibrotic tissue, and control the development of the disease. -
Key words:
- Oral submucosal fibrosis /
- Nd: YAG laser /
- Triamcinolone acetonide /
- IL-6 /
- TNF-α
-
表 1 2组口腔黏膜下纤维化患者VAS评分、张口程度及口腔黏膜病损面积比较(x±s)
组别 例数 VAS评分(分) 张口程度(mm) 口腔黏膜病损面积(cm2) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 40 4.17±1.72 0.96±0.32a 22.58±3.75 29.85±2.18a 6.05±1.32 1.47±0.62a 观察组 40 3.85±1.68 0.84±0.33a 22.46±4.12 32.28±2.13a 5.94±1.37 0.86±0.23a t值 0.842 1.651 0.136 5.042 0.366 5.834 P值 0.402 0.103 0.892 <0.001 0.716 <0.001 注:与治疗前比较,aP < 0.05。 表 2 2组口腔黏膜下纤维化患者血清VEGF、TSP和MMP-2水平比较(x±s)
组别 例数 VEGF(pg/mL) TSP(ng/mL) MMP-2(μg/mL) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 40 0.48±0.12 0.61±0.23a 1.62±0.51 1.22±0.31a 1.08±0.27 0.51±0.19a 观察组 40 0.43±0.11 0.75±0.19a 1.59±0.46 1.02±0.22a 1.15±0.21 0.37±0.15a t值 1.943 2.968 0.276 3.328 1.294 3.658 P值 0.056 0.004 0.783 0.001 0.199 <0.001 注:与治疗前比较,aP < 0.05。 表 3 2组口腔黏膜下纤维化患者血清IL-6、TNF-α水平比较(x±s)
组别 例数 IL-6(ng/L) TNF-α(μg/L) 治疗前 治疗后 治疗前 治疗后 对照组 40 22.71±2.65 16.87±2.03a 16.39±1.98 13.84±1.32a 观察组 40 23.12±2.07 15.26±2.12a 16.07±2.11 12.15±1.31a t值 0.771 3.469 0.699 5.747 P值 0.443 <0.001 0.486 <0.001 注:与治疗前比较,aP < 0.05。 -
[1] RAY J G, RANGANATHAN K, CHATTAPADHYAY A. Malignant transformation of oral submucous fibrosis: Overview of histopathological aspects[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(2): 200-209. doi: 10.1016/j.oooo.2015.11.024 [2] YANG S F, WANG Y H, SU N Y, et al. Changes in prevalence of precancerous oral submucous fibrosis from 1996 to 2013 in Taiwan: A nationwide population-based retrospective study[J]. J Formos Med Assoc, 2018, 117(2): 147-152. doi: 10.1016/j.jfma.2017.01.012 [3] MOSTAFA M G, KHAN J A, AHMED S, et al. Comparison between efficacy of combined use of hyaluronidise and triamcinolone versus hyaluronidise, triamcinolone acetonide and oral colchicine in the treatment of oral submucous fibrosis[J]. Mymensingh Med J, 2021, 30(1): 79-84. [4] GOTTIPAMULA S, SUNDARRAJAN S, MOORTHY A, et al. Buccal mucosal epithelial cells downregulate CTGF expression in buccal submucosal fibrosis fibroblasts[J]. J Maxillofac Oral Surg, 2018, 17(2): 254-259. doi: 10.1007/s12663-017-1056-1 [5] 柯云艳, 陈学鹏, 张立港, 等. 复方丹参滴丸联合曲安奈德治疗口腔黏膜下纤维性变的临床观察及对血清TGF-β1、IL-6的影响[J]. 中华中医药学刊, 2019, 37(8): 1974-1977. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201908044.htm [6] 汪婷, 朱亚琴. Nd: YAP激光与Er: YAG激光在口腔医学的应用现状[J]. 口腔材料器械杂志, 2018, 27(4): 225-228. https://www.cnki.com.cn/Article/CJFDTOTAL-KCCL201804013.htm [7] 俞立英. 临床口腔医学: 新进展、新技术、新理论[M]. 上海: 复旦大学出版社, 2008: 87-110. [8] 中华口腔医学会口腔黏膜病专业委员会. 口腔扁平苔藓(萎缩型、糜烂型)疗效评价标准(试行)[J]. 中华口腔医学杂志, 2005, 40(2): 92-93. doi: 10.3760/j.issn:1002-0098.2005.02.002 [9] YANG H W, YU C C, HSIEH P L, et al. Arecoline enhances miR-21 to promote buccal mucosal fibroblasts activation[J]. J Formos Med Assoc, 2021, 120(4): 1108-1113. doi: 10.1016/j.jfma.2020.10.019 [10] SHEN Y W, SHIH Y H, FUH L J, et al. Oral submucous fibrosis: A review on biomarkers, pathogenic mechanisms, and treatments[J]. Int J Mol Sci, 2020, 21(19): 7231. doi: 10.3390/ijms21197231 [11] 黎凯歌, 陈颖怡, 余程. Er: YAG激光与Nd: YAG激光在口腔医学领域中的应用[J]. 临床口腔医学杂志, 2017, 33(11): 688-690. doi: 10.3969/j.issn.1003-1634.2017.11.016 [12] OHSUGI Y, NⅡMI H, SHIMOHIRA T, et al. In vitro cytological responses against laserphotobiomodulation for periodontal regeneration[J]. Int J Mol Sci, 2020, 21(23): 9002. doi: 10.3390/ijms21239002 [13] 白真玉, 刘德裕, 陈尧卉, 等. 曲安奈德注射液对口腔黏膜下纤维化组织VEGF、TSP、MMP-2表达水平的影响[J]. 内蒙古医科大学学报, 2019, 41(6): 602-603. https://www.cnki.com.cn/Article/CJFDTOTAL-NMYX201906015.htm [14] VAN DER GEER S J, REINTSEMA H, KAMSTRA J I, et al. The use of stretching devices for treatment of trismus in head and neck cancer patients: A randomized controlled trial[J]. Support Care Cancer, 2020, 28(1): 9-11. doi: 10.1007/s00520-019-05075-7 [15] 邵霞, 丁耘峰, 王晓红, 等. HIF-1α和VEGF在不同糖代谢状态乳腺癌患者中的表达及其与微血管生成的相关性[J]. 中华全科医学, 2018, 16(2): 200-203. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201802011.htm [16] 金建祥, 谷驰. 侵袭性垂体腺瘤患者瘤组织中HIF-1α、VEGF和MMP-9表达水平及临床意义[J]. 中华全科医学, 2017, 15(5): 767-769, 910. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201705012.htm [17] 党薇, 邱忠营, 王艳丽. Nd: YAG激光联合曲安奈德治疗口腔黏膜下纤维化的效果分析[J]. 中国临床医生杂志, 2020, 48(7): 854-856. doi: 10.3969/j.issn.2095-8552.2020.07.032 [18] TANG D, TAO D, FANG Y, et al. TNF-alpha promotes invasion and metastasis via NF-kappa B pathway in oral squamous cell carcinoma[J]. Med Sci Monit Basic Res, 2017, 23: 141-149. doi: 10.12659/MSMBR.903910 [19] 项海东, 王一龙, 刘从娜, 等. Nd: YAG激光联合曲安奈德口腔软膏治疗急性放射性口炎的效果[J]. 河北医药, 2020, 42(8): 1173-1176. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202008012.htm [20] LANJEKAR A B, BHOWATE R R, BAKHLE S, et al. Comparison of efficacy of topical curcumin gel with triamcinolone-hyaluronidase gel individually and in combination in the treatment of oral submucous fibrosis[J]. J Contemp Dent Pract, 2020, 21(1): 83-90. doi: 10.5005/jp-journals-10024-2726 [21] RAJESH KASHYAP R, SHANKER KASHYAP R. Herbal derivatives in the management of mouth opening in oral submucous fibrosis-A network meta-analysis[J]. Oral Dis, 2021, 27(7): 1606-1615. doi: 10.1111/odi.13544 -

计量
- 文章访问数: 586
- HTML全文浏览量: 226
- PDF下载量: 10
- 被引次数: 0